GlassScriptPhysician profile
Madison Ross
NPI 1861019788
$1,264.59
in general payments reported to CMS, 2019-2025
19 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.53 · 2022: $36.37 · 2023: $275 · 2024: $448 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.35 | 2023-2025 | Qulipta |
| Lilly USA, LLC | $141.75 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $112.77 | 2022-2025 | |
| Pfizer INC. | $90.13 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.20 | 2021-2023 | Xifaxan |
| Axsome Therapeutics, INC. | $68.07 | 2023-2025 | Auvelity, Symbravo |
| Exact Sciences Corporation | $63.38 | 2023 | Cologuard Collection Kit |
| Ceribell, INC. | $54.36 | 2025 | Pocket Eeg Device |
| Novartis Pharmaceuticals Corporation | $46.80 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.52 | 2023-2024 | Ofev, Jardiance |
| Novo Nordisk INC | $35.72 | 2024-2025 | Ozempic, Wegovy |
| Janssen Biotech, INC. | $25.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.79 | 2025 | Caplyta |
| Sobi, INC | $21.45 | 2023 | |
| Averitas Pharma INC. | $19.05 | 2024 | Qutenza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.85 | 2025 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $14.92 | 2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $14.33 | 2024 | Airsupra |
| Eisai INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.